immunoglobulin heavy variable (II)-22-1 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored IGHVII-22-1 profile across patient tissues and cancer cell-line models. IGHVII-22-1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IGHVII-22-1 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, IGHVII-22-1 RNA expression shows 7,015 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, STAD, and THYM as cancer lineages where IGHVII-22-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHVII-22-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHVII-22-1 survival associations across molecular data types. IGHVII-22-1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHVII-22-1 RNA expression–survival associations across cancer types. High IGHVII-22-1 expression shows unfavorable associations in KIRC, DLBC, LGG and READ, but favorable associations in SKCM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for IGHVII-22-1 RNA expression.
This table summarizes IGHVII-22-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHVII-22-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHVII-22-1 shows lower tumor expression in STAD and higher tumor expression in LUAD. The STAD box plot shows higher IGHVII-22-1 RNA expression in normal versus tumor tissue (log2 FC = −0.346, t-test p = .044).
This table shows molecular features associated with IGHVII-22-1 in patient tissues and cancer cell lines. In patient samples, IGHVII-22-1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
